[1]
Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. Journal of neurology. 2017 Aug:264(8):1608-1616. doi: 10.1007/s00415-016-8377-8. Epub 2017 Jan 4
[PubMed PMID: 28054130]
[2]
Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2012 Nov-Dec:32(6):590-4. doi: 10.3747/pdi.2012.00152. Epub
[PubMed PMID: 23212858]
[3]
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. The New England journal of medicine. 1996 Feb 22:334(8):494-500
[PubMed PMID: 8559202]
[4]
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clinic proceedings. 2010 May:85(5):427-32. doi: 10.4065/mcp.2009.0590. Epub
[PubMed PMID: 20435835]
[5]
Cordelli DM, Masetti R, Ricci E, Toni F, Zama D, Maffei M, Gentili A, Parmeggiani A, Pession A, Franzoni E. Life-threatening complications of posterior reversible encephalopathy syndrome in children. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2014 Sep:18(5):632-40. doi: 10.1016/j.ejpn.2014.04.014. Epub 2014 Apr 25
[PubMed PMID: 24814477]
[6]
Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR. American journal of neuroradiology. 1998 Mar:19(3):415-7
[PubMed PMID: 9541291]
[7]
Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. The New England journal of medicine. 2006 Mar 2:354(9):980-2; discussion 980-2
[PubMed PMID: 16514715]
[8]
Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Archives of neurology. 2006 Oct:63(10):1475-8
[PubMed PMID: 17030665]
[9]
Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology. 2007 Jun 5:68(23):2039-40
[PubMed PMID: 17548556]
[10]
Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. The oncologist. 2007 Nov:12(11):1332-5
[PubMed PMID: 18055853]
Level 3 (low-level) evidence
[11]
Junna MR, Rabinstein AA. Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. Journal of neurology, neurosurgery, and psychiatry. 2007 Dec:78(12):1410-1
[PubMed PMID: 18024699]
[12]
Garner O, Ramirez A, Iardino A. A case of posterior reversible encephalopathy syndrome associated with sepsis. BMJ case reports. 2018 Jul 10:2018():. pii: bcr-2018-225128. doi: 10.1136/bcr-2018-225128. Epub 2018 Jul 10
[PubMed PMID: 29991547]
Level 3 (low-level) evidence
[13]
Chowdhary M, Kabbani AA, Tobey D, Hope TD. Posterior reversible encephalopathy syndrome in a woman with focal segmental glomerulosclerosis. Neuropsychiatric disease and treatment. 2015:11():1111-4. doi: 10.2147/NDT.S84010. Epub 2015 Apr 21
[PubMed PMID: 25960654]
[14]
Sundin CS, Johnson ML. Posterior Reversible Encephalopathy Syndrome. MCN. The American journal of maternal child nursing. 2018 Mar/Apr:43(2):77-82. doi: 10.1097/NMC.0000000000000409. Epub
[PubMed PMID: 29470266]
[15]
Faille LD, Fieuws S, Van Paesschen W. Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome. Acta neurologica Belgica. 2017 Jun:117(2):469-475. doi: 10.1007/s13760-017-0750-6. Epub 2017 Jan 31
[PubMed PMID: 28144796]
[16]
Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR. American journal of neuroradiology. 2002 Jun-Jul:23(6):1038-48
[PubMed PMID: 12063238]
[17]
Edvinsson L, Owman C, Sjöberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain research. 1976 Oct 22:115(3):377-93
[PubMed PMID: 184880]
[18]
Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR. American journal of neuroradiology. 2008 Jun:29(6):1036-42. doi: 10.3174/ajnr.A0928. Epub 2008 Mar 20
[PubMed PMID: 18356474]
[19]
Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzalez RG, Koroshetz WJ. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998 Nov:51(5):1369-76
[PubMed PMID: 9818862]
[20]
Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology. 2001 Jun:219(3):756-65
[PubMed PMID: 11376265]
[21]
Naidu K, Moodley J, Corr P, Hoffmann M. Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia. British journal of obstetrics and gynaecology. 1997 Oct:104(10):1165-72
[PubMed PMID: 9332995]
[22]
Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. Internal medicine (Tokyo, Japan). 1999 Jan:38(1):54-8
[PubMed PMID: 10052744]
Level 3 (low-level) evidence
[23]
Lanzino G, Cloft H, Hemstreet MK, West K, Alston S, Ishitani M. Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases. Clinical neurology and neurosurgery. 1997 Aug:99(3):222-6
[PubMed PMID: 9350407]
Level 3 (low-level) evidence
[24]
Nwafor DC, Brichacek AL, Mohammad AS, Griffith J, Lucke-Wold BP, Benkovic SA, Geldenhuys WJ, Lockman PR, Brown CM. Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment. Journal of central nervous system disease. 2019:11():1179573519840652. doi: 10.1177/1179573519840652. Epub 2019 Apr 9
[PubMed PMID: 31007531]
[25]
Marra AM, Barilaro G, Villella V, Granata M. Eosinophilic granulomatosis with polyangiitis (EGPA) and PRES: a case-based review of literature in ANCA-associated vasculitides. Rheumatology international. 2015 Sep:35(9):1591-5. doi: 10.1007/s00296-015-3261-x. Epub 2015 Apr 3
[PubMed PMID: 25836767]
Level 3 (low-level) evidence
[27]
Lifson N, Pasquale A, Salloum G, Alpert S. Ophthalmic Manifestations of Posterior Reversible Encephalopathy Syndrome. Neuro-ophthalmology (Aeolus Press). 2019 Jun:43(3):180-184. doi: 10.1080/01658107.2018.1506938. Epub 2018 Aug 17
[PubMed PMID: 31312242]
[28]
Hawatmeh A, Studyvin S, Al-Halawani M, Amireh S, Thawabi M. Posterior reversible encephalopathy syndrome associated with left horizontal gaze palsy. Annals of translational medicine. 2017 Mar:5(5):104. doi: 10.21037/atm.2017.03.09. Epub
[PubMed PMID: 28361069]
[29]
Vandenbossche G, Maquet J, Vroonen P, Lambert G, Nisolle M, Kridelka F, Emonts E. A reversible posterior leucoencephalopathy syndrome including blindness caused by preeclampsia. Facts, views & vision in ObGyn. 2016 Sep:8(3):173-177
[PubMed PMID: 28003872]
[30]
Zou LP, Liu LY, Li H, Wang YY, Liu Y, Chen J, Hu LY, Liu MJ, Zhang MN, Lu Q, Ma SF. Establishment and utility assessment of posterior reversible encephalopathy syndrome early warning scoring (PEWS) scale establishment and utility assessment of PEWS scale. BMC neurology. 2019 Feb 21:19(1):30. doi: 10.1186/s12883-019-1247-0. Epub 2019 Feb 21
[PubMed PMID: 30791893]
[31]
Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR. American journal of neuroradiology. 2008 Mar:29(3):447-55
[PubMed PMID: 18079186]
[32]
Murray K, Amin U, Maciver S, Benbadis SR. EEG Findings in Posterior Reversible Encephalopathy Syndrome. Clinical EEG and neuroscience. 2019 Sep:50(5):366-369. doi: 10.1177/1550059419856968. Epub 2019 Jun 19
[PubMed PMID: 31215229]
[33]
Strother R, Wong H, Miller NE. Posterior Reversible Encephalopathy Syndrome Secondary to Hypertensive Encephalopathy Brought on by a MAO Inhibitor: A Case Report. Journal of primary care & community health. 2019 Jan-Dec:10():2150132719869539. doi: 10.1177/2150132719869539. Epub
[PubMed PMID: 31423884]
Level 3 (low-level) evidence
[34]
Gokhale A, Kimona A, Kantor S, Prakash S, Manhas Y. Posterior Reversible Leukoencephalopathy Syndrome (PRES) in Intensive Care Unit - Case series. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2017 Nov:21(11):772-778. doi: 10.4103/ijccm.IJCCM_235_17. Epub
[PubMed PMID: 29279639]
[35]
Spencer D. PRES-ing for Answers About Long-Term Seizure Risk in Patients With Posterior Reversible Encephalopathy Syndrome. Epilepsy currents. 2015 Nov-Dec:15(6):317-8. doi: 10.5698/1535-7511-15.6.317. Epub
[PubMed PMID: 26633947]
[36]
Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what's certain, what's new? Practical neurology. 2011 Jun:11(3):136-44. doi: 10.1136/practneurol-2011-000010. Epub
[PubMed PMID: 21551107]
[37]
Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. Journal of neurology. 1999 May:246(5):339-46
[PubMed PMID: 10399863]
[38]
Atça AÖ, Erok B, Aydoğdu S. Neuroimaging findings of posterior reversible encephalopathy syndrome (PRES) following haematopoietic stem cell transplantation in paediatric recipients. BMC pediatrics. 2021 Oct 11:21(1):445. doi: 10.1186/s12887-021-02890-y. Epub 2021 Oct 11
[PubMed PMID: 34629063]